Millions Use Ozempic Without Medical Need

A significant analysis of over 92 million U.S. adults has uncovered that more than 1.1 million individuals are using GLP-1 medications without qualifying medical conditions like obesity or diabetes. The study, published in the journal Obesity, highlights a dramatic 15-fold increase in these off-label prescriptions between 2021 and 2025. This trend suggests many are seeking the drugs for weight loss or potential unapproved benefits, fueled by public discourse and aggressive marketing.

Doctors note that while GLP-1s are FDA-approved for obesity, diabetes, and certain cardiovascular or kidney conditions, their off-label use is expanding. Over a third of those using the drugs without a prescription had a normal body mass index. Some patients also showed higher instances of eating disorders, high blood pressure, or high cholesterol. Scientists are exploring other uses, such as fertility or curbing cravings, but data is limited.

Concerns are mounting among medical professionals regarding the safety and comprehensive care provided for these off-label prescriptions. Experts like Dr. Andrew Kraftson question whether doctors are fully assessing patients' needs and potential risks. Given that these drugs were largely excluded from clinical trials for individuals without obesity, the long-term effects remain unknown, leading some to call this a "big Ozempic experiment."